Scott N - Search Results

1

Enhancing the hepatitis B care cascade in Australia: A cost-effectiveness model.

Xiao Y, Howell J, van Gemert C, Thompson AJ, Seaman CP, McCulloch K, Scott N, Hellard ME. Xiao Y, et al. Among authors: scott n. J Viral Hepat. 2020 May;27(5):526-536. doi: 10.1111/jvh.13252. Epub 2020 Jan 3. J Viral Hepat. 2020. PMID: 31856377

2

The changing landscape of hepatitis C treatment-not 'can we cure?' but 'who should we cure first?' Is this an ethical approach?

Hellard M, Scott N. Hellard M, et al. Among authors: scott n. Addiction. 2015 Jun;110(6):984-5. doi: 10.1111/add.12912. Addiction. 2015. PMID: 25963872 No abstract available.

3

The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.

Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M. Scott N, et al. BMC Med. 2015 Aug 20;13:198. doi: 10.1186/s12916-015-0440-2. BMC Med. 2015. PMID: 26289050 Free PMC article.

4

Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.

Scott N, Hellard M, McBryde ES. Scott N, et al. Virulence. 2016;7(2):201-8. doi: 10.1080/21505594.2015.1085151. Epub 2015 Aug 25. Virulence. 2016. PMID: 26305706 Free PMC article. Review.

5

Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.

Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME. Scott N, et al. J Gastroenterol Hepatol. 2016 Apr;31(4):872-82. doi: 10.1111/jgh.13223. J Gastroenterol Hepatol. 2016. PMID: 26514998

6

Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.

Scott N, McBryde ES, Thompson A, Doyle JS, Hellard ME. Scott N, et al. Gut. 2017 Aug;66(8):1507-1515. doi: 10.1136/gutjnl-2016-311504. Epub 2016 Apr 12. Gut. 2017. PMID: 27196586

7

The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?

Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P. Stone J, et al. Among authors: scott n. PLoS One. 2016 May 25;11(5):e0156213. doi: 10.1371/journal.pone.0156213. eCollection 2016. PLoS One. 2016. PMID: 27224423 Free PMC article.

8

Targeted direct-acting antiviral treatment for chronic hepatitis C: A financial reality or an obstacle to elimination?

Hellard M, Pedrana A, Scott N. Hellard M, et al. Among authors: scott n. J Hepatol. 2017 Feb;66(2):270-272. doi: 10.1016/j.jhep.2016.11.007. Epub 2016 Nov 22. J Hepatol. 2017. PMID: 27884764 No abstract available.

9

Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.

Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME. Scott N, et al. Int J Drug Policy. 2017 Sep;47:107-116. doi: 10.1016/j.drugpo.2017.07.006. Epub 2017 Aug 7. Int J Drug Policy. 2017. PMID: 28797497

10

Achieving 90-90-90 Human Immunodeficiency Virus (HIV) Targets Will Not Be Enough to Achieve the HIV Incidence Reduction Target in Australia.

Scott N, Stoové M, Kelly SL, Wilson DP, Hellard ME. Scott N, et al. Clin Infect Dis. 2018 Mar 19;66(7):1019-1023. doi: 10.1093/cid/cix939. Clin Infect Dis. 2018. PMID: 29099920

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,525 results

Search Page

Filters